20301360|t|Citrin Deficiency
20301360|a|CLINICAL CHARACTERISTICS: Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. <b>NICCD.</b> Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. <b>FTTDCD.</b> Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. <b>CTLN2.</b> Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD. DIAGNOSIS/TESTING: The diagnosis of citrin deficiency is established in an individual with characteristic biochemical findings (in general, increased blood or plasma concentration of ammonia, plasma or serum concentration of citrulline and arginine, plasma or serum threonine-to-serine ratio, and serum concentration of pancreatic secretory trypsin inhibitor) and identification of biallelic pathogenic variants in <i>SLC25A13</i>. MANAGEMENT: <i>Treatment of manifestations:</i> NICCD: Supplement diet with fat-soluble vitamins and use of lactose-free and medium-chain triglyceride (MCT)-enriched formula. FTTDCD: In addition to dietary treatment, administration of sodium pyruvate may improve growth. CTLN2: Liver transplantation prevents hyperammonemic crises, corrects metabolic disturbances, and eliminates preferences for protein-rich foods; arginine administration decreases blood ammonia concentration and reduced calorie/carbohydrate intake; increased protein intake lessens hypertriglyceridemia. Use of arginine, sodium pyruvate, and MCT oil may delay the need for liver transplantation. <i>Prevention of primary manifestations:</i> Lipid and protein-rich low-carbohydrate diet. <i>Surveillance:</i> Periodic measurement of plasma concentration of ammonia and citrulline, and serum concentration of PSTI for all phenotypes associated with citrin deficiency. Follow up of children who have had NICCD for the laboratory and physical findings of FTTDCD. <i>Agents/circumstances to avoid:</i> Low-protein high-carbohydrate diets; glycerol and fructose infusions for brain edema; alcohol; acetaminophen and rabeprozole. <i>Evaluation of relatives at risk:</i> It is appropriate to identify affected sibs of a proband so that appropriate dietary management can be instituted before symptoms occur. GENETIC COUNSELING: Citrin deficiency is inherited in an autosomal recessive manner. When both parents are carriers of an <i>SLC25A13</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. When one parent is a carrier and the other parent has two <i>SLC25A13</i> pathogenic variants, each sib of an affected individual has at conception a 50% chance of being affected and a 50% chance of being an asymptomatic carrier. Testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are possible if the <i>SLC25A13</i> pathogenic variants in the family are known.
20301360	0	17	Citrin Deficiency	Disease	MESH:C538053
20301360	44	61	Citrin deficiency	Disease	MESH:C538053
20301360	101	162	neonatal intrahepatic cholestasis caused by citrin deficiency	Disease	MESH:C536398
20301360	164	169	NICCD	Disease	MESH:C536398
20301360	193	210	failure to thrive	Disease	MESH:D005183
20301360	215	227	dyslipidemia	Disease	MESH:D050171
20301360	238	255	citrin deficiency	Disease	MESH:C538053
20301360	257	263	FTTDCD	Disease	
20301360	293	307	hyperammonemia	Disease	MESH:D022124
20301360	313	338	neuropsychiatric symptoms	Disease	MESH:D001523
20301360	342	363	citrullinemia type II	Disease	MESH:C538053
20301360	365	370	CTLN2	Disease	MESH:C538053
20301360	379	396	citrin deficiency	Disease	MESH:C538053
20301360	459	464	lipid	Chemical	MESH:D008055
20301360	492	504	carbohydrate	Chemical	MESH:D002241
20301360	520	525	NICCD	Disease	MESH:C536398
20301360	606	624	growth restriction	Disease	MESH:D005317
20301360	639	663	intrahepatic cholestasis	Disease	MESH:D002780
20301360	665	677	hepatomegaly	Disease	MESH:D006529
20301360	687	698	fatty liver	Disease	MESH:D005234
20301360	754	770	hepatic fibrosis	Disease	MESH:D008103
20301360	781	798	liver dysfunction	Disease	MESH:D017093
20301360	800	815	hypoproteinemia	Disease	MESH:D007019
20301360	817	846	decreased coagulation factors	Disease	MESH:D020147
20301360	848	864	hemolytic anemia	Disease	MESH:D000743
20301360	873	885	hypoglycemia	Disease	MESH:D007003
20301360	887	892	NICCD	Disease	MESH:C536398
20301360	1059	1065	FTTDCD	Disease	
20301360	1111	1128	citrin deficiency	Disease	MESH:C538053
20301360	1159	1164	lipid	Chemical	MESH:D008055
20301360	1202	1214	carbohydrate	Chemical	MESH:D002241
20301360	1236	1249	abnormalities	Disease	MESH:D000014
20301360	1262	1280	growth restriction	Disease	MESH:D005317
20301360	1282	1294	hypoglycemia	Disease	MESH:D007003
20301360	1296	1308	pancreatitis	Disease	MESH:D010195
20301360	1317	1324	fatigue	Disease	MESH:D005221
20301360	1326	1334	anorexia	Disease	MESH:D000855
20301360	1340	1364	impaired quality of life	Disease	MESH:D003643
20301360	1389	1401	dyslipidemia	Disease	MESH:D050171
20301360	1413	1420	lactate	Chemical	MESH:D019344
20301360	1424	1432	pyruvate	Chemical	MESH:D019289
20301360	1521	1539	tricarboxylic acid	Chemical	MESH:D014233
20301360	1541	1544	TCA	Chemical	MESH:D014233
20301360	1614	1619	NICCD	Disease	MESH:C536398
20301360	1623	1629	FTTDCD	Disease	
20301360	1638	1643	CTLN2	Disease	MESH:C538053
20301360	1648	1653	CTLN2	Disease	MESH:C538053
20301360	1724	1738	Manifestations	Disease	MESH:D012877
20301360	1753	1767	hyperammonemia	Disease	MESH:D022124
20301360	1773	1798	neuropsychiatric symptoms	Disease	MESH:D001523
20301360	1819	1827	delirium	Disease	MESH:D003693
20301360	1829	1839	aggression	Disease	MESH:D010554
20301360	1841	1853	irritability	Disease	MESH:D001523
20301360	1855	1868	hyperactivity	Disease	MESH:D006948
20301360	1870	1879	delusions	Disease	MESH:D063726
20301360	1881	1895	disorientation	Disease	MESH:D003221
20301360	1897	1909	restlessness	Disease	MESH:D011595
20301360	1923	1937	loss of memory	Disease	MESH:D008569
20301360	1948	1954	tremor	Disease	MESH:D014202
20301360	1956	1975	convulsive seizures	Disease	MESH:D012640
20301360	1981	1985	coma	Disease	MESH:D003128
20301360	2018	2025	alcohol	Chemical	MESH:D000438
20301360	2030	2035	sugar	Chemical	MESH:D000073893
20301360	2132	2137	NICCD	Disease	MESH:C536398
20301360	2141	2147	FTTDCD	Disease	
20301360	2185	2202	citrin deficiency	Disease	MESH:C538053
20301360	2332	2339	ammonia	Chemical	MESH:D000641
20301360	2374	2384	citrulline	Chemical	MESH:D002956
20301360	2389	2397	arginine	Chemical	MESH:D001120
20301360	2415	2424	threonine	Chemical	MESH:D013912
20301360	2428	2434	serine	Chemical	MESH:D012694
20301360	2469	2507	pancreatic secretory trypsin inhibitor	Gene	6690
20301360	2567	2575	SLC25A13	Gene	10165
20301360	2609	2623	manifestations	Disease	MESH:D012877
20301360	2629	2634	NICCD	Disease	MESH:C536398
20301360	2657	2660	fat	Chemical	MESH:D005223
20301360	2689	2696	lactose	Chemical	MESH:D007785
20301360	2706	2731	medium-chain triglyceride	Chemical	MESH:C000709826
20301360	2733	2736	MCT	Chemical	MESH:C000709826
20301360	2756	2762	FTTDCD	Disease	
20301360	2816	2831	sodium pyruvate	Chemical	-
20301360	2852	2857	CTLN2	Disease	MESH:C538053
20301360	2890	2911	hyperammonemic crises	Disease	MESH:D013224
20301360	2922	2944	metabolic disturbances	Disease	MESH:D024821
20301360	2997	3005	arginine	Chemical	MESH:D001120
20301360	3037	3044	ammonia	Chemical	MESH:D000641
20301360	3079	3091	carbohydrate	Chemical	MESH:D002241
20301360	3133	3153	hypertriglyceridemia	Disease	MESH:D015228
20301360	3162	3170	arginine	Chemical	MESH:D001120
20301360	3172	3187	sodium pyruvate	Chemical	-
20301360	3193	3200	MCT oil	Chemical	-
20301360	3272	3286	manifestations	Disease	MESH:D012877
20301360	3292	3297	Lipid	Chemical	MESH:D008055
20301360	3319	3331	carbohydrate	Chemical	MESH:D002241
20301360	3407	3414	ammonia	Chemical	MESH:D000641
20301360	3419	3429	citrulline	Chemical	MESH:D002956
20301360	3498	3515	citrin deficiency	Disease	MESH:C538053
20301360	3552	3557	NICCD	Disease	MESH:C536398
20301360	3602	3608	FTTDCD	Disease	
20301360	3665	3677	carbohydrate	Chemical	MESH:D002241
20301360	3685	3693	glycerol	Chemical	MESH:D005990
20301360	3698	3706	fructose	Chemical	MESH:D005632
20301360	3721	3732	brain edema	Disease	MESH:D001929
20301360	3734	3741	alcohol	Chemical	MESH:D000438
20301360	3743	3756	acetaminophen	Chemical	MESH:D000082
20301360	3761	3772	rabeprozole	Chemical	-
20301360	3951	3969	GENETIC COUNSELING	Disease	MESH:D030342
20301360	3971	3988	Citrin deficiency	Disease	MESH:C538053
20301360	4076	4084	SLC25A13	Gene	10165
20301360	4358	4366	SLC25A13	Gene	10165
20301360	4635	4643	SLC25A13	Gene	10165
20301360	Association	MESH:C000709826	MESH:D030342
20301360	Association	MESH:D014233	MESH:C538053
20301360	Positive_Correlation	MESH:D000073893	MESH:D012640
20301360	Positive_Correlation	MESH:D000438	MESH:D022124
20301360	Association	MESH:D005990	MESH:D013224
20301360	Association	MESH:D030342	10165
20301360	Association	MESH:D005632	MESH:D013224
20301360	Negative_Correlation	MESH:C538053	6690
20301360	Association	MESH:D000082	10165
20301360	Association	MESH:D007785	MESH:D030342
20301360	Association	MESH:D000082	MESH:D005223
20301360	Association	MESH:C000709826	MESH:D007785
20301360	Association	MESH:D000641	MESH:C538053
20301360	Association	MESH:D005223	MESH:D005990
20301360	Association	MESH:D000082	MESH:D005990
20301360	Association	MESH:D005223	10165
20301360	Association	MESH:D005223	MESH:D015228
20301360	Association	MESH:D000082	MESH:D013224
20301360	Association	MESH:D013224	10165
20301360	Association	MESH:D005990	10165
20301360	Association	MESH:D007785	MESH:D024821
20301360	Association	MESH:C000709826	10165
20301360	Association	MESH:D013912	MESH:C538053
20301360	Association	MESH:D005990	MESH:D030342
20301360	Association	MESH:D005223	MESH:D030342
20301360	Association	MESH:D008055	MESH:C538053
20301360	Association	MESH:D005632	10165
20301360	Association	MESH:D015228	10165
20301360	Association	MESH:C538053	10165
20301360	Positive_Correlation	MESH:D000438	MESH:D012640
20301360	Association	MESH:D000082	MESH:D015228
20301360	Association	MESH:C000709826	MESH:D005223
20301360	Association	MESH:C000709826	MESH:D013224
20301360	Association	MESH:D005990	MESH:D024821
20301360	Association	MESH:D005223	MESH:D024821
20301360	Association	MESH:D000082	MESH:D005632
20301360	Association	MESH:D005990	MESH:D001929
20301360	Association	MESH:D007785	10165
20301360	Association	MESH:D002956	MESH:C538053
20301360	Association	MESH:D005223	MESH:D001929
20301360	Association	MESH:D012694	MESH:C538053
20301360	Positive_Correlation	MESH:D000073893	MESH:D014202
20301360	Association	MESH:D024821	10165
20301360	Association	MESH:D000082	MESH:D030342
20301360	Association	MESH:C000709826	MESH:D015228
20301360	Positive_Correlation	MESH:D000438	MESH:D003221
20301360	Association	MESH:D005632	MESH:D001929
20301360	Association	MESH:D007785	MESH:D015228
20301360	Association	MESH:D007785	MESH:D013224
20301360	Association	MESH:D005632	MESH:D015228
20301360	Positive_Correlation	MESH:D000438	MESH:D063726
20301360	Positive_Correlation	MESH:D000438	MESH:D008569
20301360	Association	MESH:D000082	MESH:D024821
20301360	Positive_Correlation	MESH:D000073893	MESH:D003128
20301360	Association	MESH:D000082	MESH:D007785
20301360	Association	MESH:D002241	MESH:C538053
20301360	Association	MESH:D005632	MESH:D030342
20301360	Association	MESH:D000082	MESH:D001929
20301360	Association	MESH:D001929	10165
20301360	Association	MESH:C000709826	MESH:D024821
20301360	Positive_Correlation	MESH:D000438	MESH:D014202
20301360	Association	MESH:D002241	MESH:D013224
20301360	Positive_Correlation	MESH:D000438	MESH:D011595
20301360	Association	MESH:D005990	MESH:D015228
20301360	Positive_Correlation	MESH:D000438	MESH:D001523
20301360	Association	MESH:C000709826	MESH:D000082
20301360	Association	MESH:D007785	MESH:D001929
20301360	Association	MESH:D005223	MESH:D013224
20301360	Positive_Correlation	MESH:D000438	MESH:D003693
20301360	Association	MESH:C000709826	MESH:D001929
20301360	Association	MESH:D001120	MESH:C538053
20301360	Association	MESH:D005632	MESH:D024821
20301360	Positive_Correlation	MESH:D000438	MESH:D003128

